Compare CABO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | CNTA |
|---|---|---|
| Founded | 1980 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.1M | 2.3B |
| IPO Year | N/A | 2021 |
| Metric | CABO | CNTA |
|---|---|---|
| Price | $132.34 | $26.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $126.00 | $37.70 |
| AVG Volume (30 Days) | 147.0K | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,524,897,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 118.88 |
| 52 Week Low | $96.67 | $9.60 |
| 52 Week High | $390.25 | $30.58 |
| Indicator | CABO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 45.51 |
| Support Level | $119.44 | $28.43 |
| Resistance Level | $128.95 | $30.02 |
| Average True Range (ATR) | 6.61 | 1.34 |
| MACD | 3.79 | -0.40 |
| Stochastic Oscillator | 87.37 | 18.64 |
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.